牛乳腺炎市場機會、成長動力、產業趨勢分析及 2025-2034 年預測

2024 年全球牛乳腺炎市場價值為 20 億美元，預計 2025 年至 2034 年的複合年成長率為 6.3%。這一擴張受到幾個關鍵因素的推動，包括牛乳腺炎發病率的上升、人們對動物健康的認知的提高以及全球對乳製品的需求不斷成長。隨著乳製品行業不斷擴大經營規模以滿足不斷成長的全球需求，對有效的疾病管理解決方案的需求也日益加劇。

農民和乳製品生產商更加重視改善牛隻的健康和生產力，這推動了對先進診斷工具和創新治療方案的投資。此外，對永續乳牛養殖的高度關注促使市場參與者探索非抗生素療法，如益生菌和疫苗，以解決乳房炎問題，同時減輕抗菌素抗藥性。這些全行業的努力正在培育強勁的市場格局，使牛乳腺炎治療成為獸醫學的關鍵成長領域。

市場分為藥品和診斷。醫藥部門包括抗生素、疫苗和其他旨在對抗乳牛感染的治療解決方案。青黴素和頭孢菌素等抗生素仍廣泛用於乳房炎治療，而乳房內灌注療法的持續創新正在提高治療效果。隨著乳製品生產商尋求快速有效的解決方案，製藥公司正致力於改進藥物配方，以降低抗生素抗藥性並提高受感染牛隻的康復率。同時，由於早期檢測方法的採用日益增多，診斷領域正在穩步成長，從而可以及時干預並更好地管理畜群。

牛乳腺炎市場根據類型進一步分為臨床乳房炎和亞臨床乳房炎。 2024 年，臨床乳房炎佔了 55% 的市場佔有率，這主要是因為其症狀明顯且對牛奶產量有重大影響。臨床乳房炎會造成直接的經濟損失，因此成為酪農和獸醫的首要任務。人們對這種疾病的認知不斷提高，以及可用的治療選擇範圍不斷擴大，正在推動市場的成長。同時，對抗生素抗藥性的擔憂正推動該行業尋求替代治療方法。非抗生素療法，包括益生菌、疫苗和草藥配方，作為符合監管變化和消費者對無抗生素乳製品需求的永續解決方案，正受到越來越多的關注。

2024 年美國牛乳腺炎產業價值為 6.83 億美元，反映了近年來的持續成長。該國牲畜數量龐大，加上對高品質牛奶的需求不斷增加，推動了乳牛養殖和獸醫服務的擴張。由於高度重視牛隻的健康，酪農正在採用更為複雜的治療方案和精準畜牧技術。預計這一趨勢將進一步加速牛乳腺炎管理的進步，鞏固美國市場在獸醫創新和乳製品生產力方面的領導地位。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 全球乳製品消費量不斷成長
    • 乳腺炎檢測技術的進展
    • 動物健康意識不斷增強
  • 產業陷阱與挑戰
    • 治療費用高
    • 抗生素抗藥性問題
• 成長潛力分析
• 監管格局
• 未來市場趨勢
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按產品，2021 - 2034 年

• 主要趨勢
• 製藥
  • 抗生素
  • 疫苗
  • 其他藥品
• 診斷

第6章：市場估計與預測：按類型，2021 - 2034 年

• 主要趨勢
• 臨床乳腺炎
• 亞臨床性乳腺炎

第7章：市場估計與預測：按管理路線，2021 - 2034 年

• 主要趨勢
• 乳房內
• 系統性

第8章：市場估計與預測：依最終用途，2021 - 2034 年

• 主要趨勢
• 獸醫醫院和診所
• 診斷實驗室
• 其他最終用途

第9章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Advanced Animal Diagnostics
• Boehringer Ingelheim
• Ceva
• DeLaval
• Elanco
• Heilsaa
• HIPPRA
• ImmuCell Corporation
• Merck & Co
• Norbrook
• Virbac
• Zoetis

The Global Bovine Mastitis Market, valued at USD 2 billion in 2024, is projected to grow at a CAGR of 6.3% from 2025 to 2034. This expansion is driven by several key factors, including the rising incidence of bovine mastitis, increasing awareness about animal health, and a growing demand for dairy products worldwide. As the dairy industry continues to scale up operations to meet the surging global demand, the need for effective disease management solutions has intensified.

Farmers and dairy producers are placing greater emphasis on improving cattle health and productivity, which is fueling investments in advanced diagnostic tools and innovative treatment solutions. Additionally, the heightened focus on sustainable dairy farming is prompting market players to explore non-antibiotic therapies, such as probiotics and vaccines, to address mastitis concerns while mitigating antimicrobial resistance. These industry-wide efforts are fostering a robust market landscape, making bovine mastitis treatment a critical area of growth in veterinary medicine.

The market is segmented into pharmaceuticals and diagnostics. The pharmaceutical segment includes antibiotics, vaccines, and other treatment solutions aimed at combating infections in dairy cattle. Antibiotics such as penicillin and cephalosporin remain widely used for mastitis treatment, while ongoing innovations in intramammary infusion therapies are enhancing treatment efficacy. With dairy producers seeking fast and effective solutions, pharmaceutical companies are focusing on improving drug formulations to reduce antibiotic resistance and improve recovery rates in affected cattle. Meanwhile, the diagnostics segment is experiencing steady growth due to the increasing adoption of early detection methods, allowing for timely intervention and better herd management.

The bovine mastitis market is further categorized by type into clinical and subclinical mastitis. In 2024, clinical mastitis accounted for 55% of the market, primarily due to its visible symptoms and the significant impact on milk production. The immediate economic losses associated with clinical mastitis make it a top priority for dairy farmers and veterinarians. Growing awareness about the condition, along with a wider range of available treatment options, is supporting market growth. At the same time, concerns over antimicrobial resistance are pushing the industry towards alternative treatment approaches. Non-antibiotic therapies, including probiotics, vaccines, and herbal formulations, are gaining traction as sustainable solutions that align with regulatory shifts and consumer demand for antibiotic-free dairy products.

The U.S. Bovine Mastitis Industry was valued at USD 683 million in 2024, reflecting consistent growth over recent years. The country's large livestock population, coupled with increasing demand for high-quality milk, is driving expansion in dairy farming and veterinary services. With a strong emphasis on cattle health, dairy farmers are adopting more sophisticated treatment solutions and precision livestock farming technologies. This trend is expected to further accelerate advancements in bovine mastitis management, reinforcing the U.S. market's leadership in veterinary innovation and dairy productivity.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising global dairy consumption
    • 3.2.1.2 Advancements in mastitis detection technologies
    • 3.2.1.3 Growing awareness of animal health
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High treatment costs
    • 3.2.2.2 Antibiotic resistance concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Pharmaceutical
  • 5.2.1 Antibiotics
  • 5.2.2 Vaccines
  • 5.2.3 Other pharmaceuticals
• 5.3 Diagnostics

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Clinical mastitis
• 6.3 Sub-clinical mastitis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Intra-mammary
• 7.3 Systemic

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals and clinics
• 8.3 Diagnostic laboratories
• 8.4 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Advanced Animal Diagnostics
• 10.2 Boehringer Ingelheim
• 10.3 Ceva
• 10.4 DeLaval
• 10.5 Elanco
• 10.6 Heilsaa
• 10.7 HIPPRA
• 10.8 ImmuCell Corporation
• 10.9 Merck & Co
• 10.10 Norbrook
• 10.11 Virbac
• 10.12 Zoetis